Trans-Arterial Embolization (TAE) is the Best Locoregional Treatment Option for Patients with Liver Metastases from Neuroendocrine Tumors Abstract #528

Introduction: Trans-arterial embolization (TAE) and chemoembolization (TACE) have been shown to be effective in patients (pts) with liver metastases (LM) from gastroenteropancreatic neuroendocrine tumor (GEP NET). TAE and TACE goal is to reduce blood flow to the tumor resulting in ischemia and necrosi.
Aim(s): Which procedure, among TAE and TACE, represent the best option in NET pts is still debated. Criteria to predict response to TAE/TACE other than objective tumor response are not defined. This challenge represents the purpose of this retrospective investigation.
Materials and methods: Forty pts (26 M, 14 F; mean age 61 yrs) with GEP NET with LM, 16 of whom with a functioning tumor were investigated. TAE was performed in 27 and TACE in 18 pts. Contrast-enhanced CT scans were performed at baseline and then after two and six months by these procedures. Change in tumor size and degree of devascularization, as compared to the baseline evaluation, were considered.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Michela Del Prete
Keywords: TAE, TACE, NET

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1888 Selective Transarterial Embolization of Gastro-Entero Pancreatic (GEP) Neuroendocrine Tumors (NET) with Advanced Locoregional Disease and/or Liver Metastases
Introduction: Selective transarterial embolization(TAE) and chemoembolization(TACE),are alternative options to systemic therapies in patients with GEP-NET G1/G2 with advanced locoregional disease and/or unresectable liver metastases
Conference: 14th Annual ENETS conference (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Dr Concepcion Blanco
Keywords: TACE, TAE, GEP-NET
#926 Transarterial (Chemo)embolization for Patients with Liver Metastasis of Neuroendocrine Tumors
Introduction: Neuroendocrine Tumors (NETs) are slowly growing tumors with an indolent course. NETs often present with liver metastasis, and most of these tumors are inoperable at the time of presentation. Transarterial (chemo)embolization [TA(C)E] is widely available to manage liver metastasis of NET.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Others
Presenting Author: Hiroyuki Okuyama
#904 Role of Metformin on Recurrence-Free Survival (RFS) in Neuroendocrine Tumors (NET)
Introduction: Recent data suggest metformin (Met) has antineoplastic properties in different type of cancer. Effects of Met have never been investigated in NET.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Others
Presenting Author: Francesca Marciello
#726 Expression and Phosphorilation of mTOR Pathway and Antitumor Activity of mTOR Inhibitors in Neuroendocrine Tumors
Introduction: The mammalian target of rapamycin (mTOR) is a protein kinase involved in the control of cancer cell metabolism, growth and proliferation. The mTOR pathway has attracted broad scientific and clinical interest, particularly in light of the ongoing clinical cancer trials with mTOR inhibitors in pts with neuroendocrine tumors (NETs). To identify the best candidates for treatment with mTOR inhibitors is challenging.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Concetta Sciammarella
#541 Contrast-Enhanced Ultrasound (CEUS) is a Helpful Tool to Predict the Effectiveness of Somatostatin Analogues in Patients with Liver Metastases From Neuroendocrine Tumors
Introduction: Contrast-enhanced ultrasonography (CEUS) allows characterization of the micro-vascularization of tumor lesions. Liver metastases (LM) from neuroendocrine tumors (NET) show a typical pattern on CEUS, consistent with a rapid, intense and homogeneous enhancement (hypervascular pattern) in the arterial phase.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Valeria Ramundo